[go: up one dir, main page]

NO20062700L - Morfolinderivater som norepinefrin reopptaksinhibitorer - Google Patents

Morfolinderivater som norepinefrin reopptaksinhibitorer

Info

Publication number
NO20062700L
NO20062700L NO20062700A NO20062700A NO20062700L NO 20062700 L NO20062700 L NO 20062700L NO 20062700 A NO20062700 A NO 20062700A NO 20062700 A NO20062700 A NO 20062700A NO 20062700 L NO20062700 L NO 20062700L
Authority
NO
Norway
Prior art keywords
reuptake inhibitors
norepinephrine reuptake
morpholine derivatives
norepinephrine
inhibitors
Prior art date
Application number
NO20062700A
Other languages
English (en)
Other versions
NO336268B1 (no
Inventor
John Joseph Masters
Gordon Iain Campbell
Manuel Javier Cases-Thomas
Teresa Man
Helene Catherine Eugenie Rudyk
Magnus Wilhelm Walter
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29726235&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20062700(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO20062700L publication Critical patent/NO20062700L/no
Publication of NO336268B1 publication Critical patent/NO336268B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Forbindelser med generell formel (I) er inhibitorer av gjenopptaket av norepinefrin. Som sådan kan de være anvendelige for behandling av forstyrrelser i det sentrale og/eller periferale nervesystemet.
NO20062700A 2003-11-10 2006-06-12 Morfolinderivater som norepinefringjenopptakingsinhibitorer NO336268B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0326148.4A GB0326148D0 (en) 2003-11-10 2003-11-10 Morpholine derivatives
US53545904P 2004-01-09 2004-01-09
PCT/US2004/032771 WO2005047272A1 (en) 2003-11-10 2004-10-28 Morpholine derivatives as norepinephrine reuptake inhibitors

Publications (2)

Publication Number Publication Date
NO20062700L true NO20062700L (no) 2006-08-08
NO336268B1 NO336268B1 (no) 2015-07-06

Family

ID=29726235

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20062700A NO336268B1 (no) 2003-11-10 2006-06-12 Morfolinderivater som norepinefringjenopptakingsinhibitorer

Country Status (33)

Country Link
US (1) US7423037B2 (no)
EP (2) EP2223916A1 (no)
JP (1) JP4850068B2 (no)
KR (1) KR100783855B1 (no)
CN (1) CN1878762B (no)
AR (1) AR046927A1 (no)
AT (1) ATE478057T1 (no)
AU (1) AU2004289616B2 (no)
BR (1) BRPI0415273B8 (no)
CA (1) CA2544649C (no)
CR (1) CR8390A (no)
CY (1) CY1110796T1 (no)
DE (1) DE602004028750D1 (no)
DK (1) DK1682523T3 (no)
EA (1) EA009960B1 (no)
EC (1) ECSP066555A (no)
ES (1) ES2348872T3 (no)
GB (1) GB0326148D0 (no)
HR (1) HRP20100476T1 (no)
IL (1) IL175365A (no)
MA (1) MA28330A1 (no)
MY (1) MY141048A (no)
NO (1) NO336268B1 (no)
NZ (1) NZ546067A (no)
PE (1) PE20050491A1 (no)
PL (1) PL1682523T3 (no)
PT (1) PT1682523E (no)
SI (1) SI1682523T1 (no)
SV (1) SV2006001934A (no)
TW (1) TWI339658B (no)
UA (1) UA85198C2 (no)
WO (1) WO2005047272A1 (no)
ZA (1) ZA200603680B (no)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1889940A (zh) * 2003-12-12 2007-01-03 伊莱利利公司 热潮红、冲动控制障碍和全身性医学病症引起的人格变化的治疗
US8580776B2 (en) * 2007-07-10 2013-11-12 The Board Of Trustees Of The University Of Illinois Compositions and methods for treating neurodegenerating diseases
RU2613633C1 (ru) * 2016-03-09 2017-03-21 федеральное государственное бюджетное образовательное учреждение высшего образования "Санкт-Петербургская государственная химико-фармацевтическая академия" Министерства здравоохранения Российской Федерации (ФГБОУ ВО СПХФА Минздрава России) Хлорид 4-[(1Е)-1-(6-хлор-4-оксо-4Н-хромен-3-ил)-4-метилпент-1-ен-3-ил]морфолин-4-ия, способ его получения и противотуберкулезная активность
GB201915753D0 (en) * 2019-10-30 2019-12-11 Univ Warwick Alzheimer's disease

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2645640A (en) 1953-07-14 Phenthiazine derivatives
NL108827C (no) 1956-04-09
GB895309A (en) 1959-11-18 1962-05-02 Res Lab Dr C Janssen Nv Pyrrolidine and piperidine derivatives
US3141823A (en) 1962-09-04 1964-07-21 Res Lab Dr C Janssen N V Method for producing analgesia
US3539573A (en) 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
JPS54130587A (en) 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
US4804663A (en) 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
GB8607684D0 (en) 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
GB8908085D0 (en) 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5238945A (en) 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
EG23659A (en) 1995-03-24 2007-03-26 Lilly Co Eli Process and crystal forms of methyl-thieno-benzodiazepine
JP2001517628A (ja) 1997-09-23 2001-10-09 イーライ・リリー・アンド・カンパニー 注意欠陥／多動障害の治療法
PT1047428E (pt) * 1998-01-21 2007-09-07 Glaxo Group Ltd Utilização de morfolinol no tratamento da disfunção sexual
US6316444B1 (en) * 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
KR20090087135A (ko) * 1999-07-01 2009-08-14 파마시아 앤드 업존 캄파니 엘엘씨 고선택성 노르에피네프린 재흡수 억제제 및 그의 이용 방법
GB0120461D0 (en) 2001-08-22 2001-10-17 Astrazeneca Ab Novel compounds
GB0219687D0 (en) * 2002-08-23 2002-10-02 Lilly Co Eli Benzyl morpholine derivatives
JP2004277318A (ja) 2003-03-14 2004-10-07 Dainippon Pharmaceut Co Ltd １−（１−置換カルボニル−４−ピペリジニルメチル）ピペリジン誘導体およびそれを含有する医薬組成物
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
EP1682523A1 (en) 2006-07-26
CR8390A (es) 2007-12-07
HK1095135A1 (en) 2007-04-27
GB0326148D0 (en) 2003-12-17
KR20060086408A (ko) 2006-07-31
CA2544649C (en) 2012-08-14
ATE478057T1 (de) 2010-09-15
EA200600945A1 (ru) 2006-10-27
CA2544649A1 (en) 2005-05-26
MY141048A (en) 2010-02-25
BRPI0415273B8 (pt) 2021-05-25
AU2004289616A1 (en) 2005-05-26
US20070083046A1 (en) 2007-04-12
BRPI0415273A (pt) 2006-12-19
JP2007510720A (ja) 2007-04-26
KR100783855B1 (ko) 2007-12-10
SV2006001934A (es) 2006-02-15
IL175365A0 (en) 2006-09-05
SI1682523T1 (sl) 2010-12-31
DK1682523T3 (da) 2010-11-15
WO2005047272A1 (en) 2005-05-26
HRP20100476T1 (hr) 2010-10-31
ZA200603680B (en) 2007-07-25
ECSP066555A (es) 2006-10-17
IL175365A (en) 2011-02-28
PT1682523E (pt) 2010-09-20
NZ546067A (en) 2009-04-30
TWI339658B (en) 2011-04-01
PL1682523T3 (pl) 2011-01-31
DE602004028750D1 (de) 2010-09-30
US7423037B2 (en) 2008-09-09
UA85198C2 (ru) 2009-01-12
AU2004289616B2 (en) 2010-08-05
BRPI0415273B1 (pt) 2019-04-30
NO336268B1 (no) 2015-07-06
CN1878762B (zh) 2010-10-27
EA009960B1 (ru) 2008-04-28
EP2223916A1 (en) 2010-09-01
ES2348872T3 (es) 2010-12-16
CY1110796T1 (el) 2015-06-10
MA28330A1 (fr) 2006-12-01
TW200524885A (en) 2005-08-01
JP4850068B2 (ja) 2012-01-11
AR046927A1 (es) 2006-01-04
EP1682523B1 (en) 2010-08-18
PE20050491A1 (es) 2005-08-24
CN1878762A (zh) 2006-12-13

Similar Documents

Publication Publication Date Title
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
NO20060402L (no) 3-amino choman og 2-aminotetralinderivater
NO20071549L (no) Nye benzofuserte heteroalrylsulfamidderivater, anvendelige som anti-krampemidler
NO20050828L (no) lndol-3-svovelderivater
EA200800172A1 (ru) 2,4-диаминопиримидины как ингибиторы aurora
NO20055219L (no) Nye forbindelser
NO20056130L (no) Nye substituerte 3-svovelindoler
NO20080675L (no) P38-Map kinaseinhibitorer og metoder for deres anvendelse
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
NO20083207L (no) Inhibitorer av IAP
NO20062561L (no) Kinoliner nyttige for behandling av kardiovaskulaere sykdommer
ATE370139T1 (de) Pyrazolopyridin derivate als tgf beta hemmstoffe zur behandlung von krebs
NO20062591L (no) Difenylazetidinonderivater med kolesterolabsorpsjonsinhiberende aktivitet
NO20062020L (no) 1-amino-2-oksysubstituerte tetrahydronaftalenderivater, fremgangsmate for fremstilling derav, og deres anvendelse som antiflogistika
DK1506185T3 (da) Forbindelser og deres anvendelse som 5-HT-inhibitorer
NO20044526L (no) Hemisterlinderivater og anvendelser derav
MY141528A (en) Anilinopyrazole derivatives useful for the treatment of diabetes
NO20073631L (no) Metasubstituerte tiazolidinoner, fremgangsmate for fremstilling og anvendelse av disse som legemiddel
NO20062256L (no) Hydroksyalkylsubstituerte pyrido-7-pyrimidin-7-oner
ATE359283T1 (de) Substituierte pyrazinonverbindungen zur behandlung von entzündungen
WO2004052858A3 (en) Inhibitors of monoamine uptake
DE602004006118D1 (de) 2,3,4,5-TETRAHYDROBENZOiFöi1,4öOXAZEPIN-5-CARBONSÄUREAMID DERIVATE ALS GAMMA-SECRETASE INHIBITOREN ZUR BEHANDLUNG VON ALZHEIMER
NO20044548L (no) Fremgangsmate for fremstilling av 6-alkaliden-penemderivater
NO20051844L (no) Piperazinderivater og fremgangsmate for anvendelse derav.